Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 4,000 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. This represents a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rhonda Farnum also recently made the following trade(s):

• On Monday, November 11th, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Stock Up 8.3 %

Shares of TBPH opened at $10.47 on Friday. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $10.90. The business has a fifty day moving average of $9.45 and a 200 day moving average of $8.91.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter last year, the company earned ($0.17) EPS. On average, research analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its stake in shares of Theravance Biopharma by 21.1% in the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,349 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after purchasing an additional 7,620 shares during the period. Barclays PLC increased its position in Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 48,316 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Theravance Biopharma in the third quarter worth about $251,000. Finally, XTX Topco Ltd grew its stake in shares of Theravance Biopharma by 34.5% during the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 5,243 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.